JAMDA
Volume 5, Issue 1 , Pages 63-64 , January 2004

The Clinical Impact of Multiresistant Gram-Positive Microorganisms in Long-Term Care Facilities

References 

  1. Stevens DL , Herr D , Lampiris H , et al.   Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections . Clin Infect Dis . 2002;34:1481–1490
  2. Stevens DL, Harrison MS, Graham DR, et al. Linezolid versus vancomycin for the treatment of suspected or proven methicillin-resistant Staphylococcus species infections: A second randomized open-label clinical trial. Presented at the 40th Annual Meeting of the Infectious Disease Society of America; October 24–27, 2002; Chicago, IL. Poster 181.
  3. Birmingham MC , Raynor CR , Meagher AK , et al.   Linezolid for the treatment of multi-drug-resistant, Gram-positive infections: experience from a compassionate use program . Clin Infect Dis . 2003;36:159–168
  4. Moise PA , Forrest A , Birmingham MC , et al.   The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to vancomycin . J Antimicrob Chemother . 2002;50:1017–1026
  5. Chien JW , Kucia ML , Salata R . Use of linezolid, an oxazolidinone, in the treatment of multi-drug-resistant Gram-positive bacterial infections . Clin Infect Dis . 2000;30:146–151
  6. Babcock HM, Ritchie DJ, Christiansen E, et al. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin Infect Dis 2001;32:1373–1375. Available at: http://www.journals.uchicago.edu/CID/journal/issues/v32n9/000698/000698.web.pdf.
  7. Kuter DJ , Tillotson GS . Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid . Pharmacotherapy . 2001;21:1010–1013
  8. Zyvox (linezolid injection, linezolid tablets, linezolid for oral suspension) [product information] . Kalamazoo, MI: Pharmacia; 2002;
  9. Gerson SL , Kaplin SL , Bruss JB , et al.   Hematologic effects of linezolid: Summary of clinical experience . Antimicrob Agents Chemother . 2002;46:2723–2726
  10. French G . Safety and tolerability of linezolid . J Antimicrob Chemother . 2003;51(suppl 2):1145–1153
  11. Attassi K , Hershberger E , Alam R , et al.   Thrombocytopenia associated with linezolid therapy . Clin Infect Dis . 2002;34:695–698
  12. Synercid IV. (quinupristin/dalfopristin) [product information] . Bristol, TN: Monarch Pharmaceutical; 2002;
  13. Venezia RA , Domaracki BE , Evans AM , et al.   Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolone exposure . J Antimicrob Chemother . 2001;48:375–381
  14. Manhold C , von Rolbicki U , Brase R . Outbreaks of Staphylococcus aureus infections during treatment of late onset pneumonia with ciprofloxacin in a prospective, randomized study . Intensive Care Med . 1998;24:1327–1330
  15. Campillo B , Dupeyron C , Richardet JP . Epidemiology of hospital-acquired infections in cirrhotic patients: Effect of carriage of methicillin-resistant Staphylococcus aureus and influence of previous antibiotic therapy and norfloxacin prophylaxis . Epidemiol Infect . 2001;127:443–450

PII: S1525-8610(04)70049-3

JAMDA
Volume 5, Issue 1 , Pages 63-64 , January 2004

Article Tools